Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH
Sign Up to like & getrecommendations! Published in 2020 at "Open Biology"
DOI: 10.1098/rsob.190235
Abstract: Cancer-specific mutations can lead to peptides of unique sequence presented on MHC class I to CD8 T cells. These neoantigens can be potent tumour-rejection antigens, appear to be the driving force behind responsiveness to anti-CTLA-4… read more here.
Keywords: enhances anti; cd8; class; neoleukin enhances ... See more keywords